RituxME
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
RituxME is a clinical trial of the ME/CFS research group at the Dept. of Oncology and Medical Physics at Haukeland University Hospital, Bergen, Norway. Senior Consultant Øystein Fluge and Professor Olav Mella are the study supervisors.[1]
Studies[edit | edit source]
- 2016, Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.[2]
- 2015, B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment
Learn more[edit | edit source]
- 20 Oct 2016, The RituxME and CycloME studies – Ongoing Clinical Research in the ME/CFS Research Group
- RituxME website
References[edit | edit source]
- ↑ http://www.helse-bergen.no/en/OmOss/Avdelinger/kreft/forsking-fagutvikling/Sider/Forsking-p%C3%A5-ME.aspx
- ↑ Lunde S, Kristoffersen EK, Sapkota D, Risa K, Dahl O, Bruland O, et al. (2016) Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome. PLoS ONE 11(8): e0161226. doi:10.1371/journal.pone.0161226